Cargando…
Dupilumab Demonstrates Rapid Onset of Action in Improving Signs, Symptoms and Quality of Life in Adults with Atopic Dermatitis
INTRODUCTION: Dupilumab has significantly improved the signs, symptoms and quality of life (QoL) of patients with moderate-to-severe atopic dermatitis (AD) in randomised, controlled clinical trials. However, there is a need to assess the effectiveness and safety of dupilumab in real-world clinical p...
Autores principales: | Augustin, Matthias, Bauer, Andrea, Ertner, Konstantin, von Kiedrowski, Ralph, Schenck, Florian, Ramaker-Brunke, Jutta, Möller, Sophie, Fait, Anja, Bastian, Mike, Thaçi, Diamant |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984619/ https://www.ncbi.nlm.nih.gov/pubmed/36738405 http://dx.doi.org/10.1007/s13555-023-00894-3 |
Ejemplares similares
-
Dupilumab Treatment of Atopic Dermatitis in Routine Clinical Care: Baseline Characteristics of Patients in the PROLEAD Prospective, Observational Study
por: Thaçi, Diamant, et al.
Publicado: (2022) -
Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and Older
por: Simpson, Eric L., et al.
Publicado: (2021) -
Dupilumab for atopic dermatitis
Publicado: (2019) -
Severe atopic dermatitis and dupilumab
por: Bernardo, Wanderley, et al.
Publicado: (2023) -
Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis
por: Eichenfield, Lawrence F., et al.
Publicado: (2019)